AUTHOR=Li Tengxiang , Yao Xinsen , He Ruimin , Xue Xian , Wang Shuai , Chen Jinhu , Qiu Qingtao , Yin Yong , Tang Quan 

TITLE=Proton stereotactic centralized ablative radiation therapy for treating bulky tumor: a treatment plan study

JOURNAL=Frontiers in Oncology

VOLUME=Volume 15 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1474327

DOI=10.3389/fonc.2025.1474327

ISSN=2234-943X

ABSTRACT=ObjectiveStereotactic centralized/core ablative radiation therapy (SCART) is a novel radiotherapy approach. This study investigates the potential benefits of proton-based SCART (pSCART) by leveraging the dosimetric advantages of protons and integrating them with the SCART technique.MethodsFive clinical cases previously treated with conventional proton therapy were selected for this study. The pSCART plans utilized a relative biological effectiveness (RBE) prescription dose of 24 Gy (RBE) × 3 fractions, with each plan consisting of three to five fields. The prescribed dose for the CyberKnife SCART was the highest value meeting the organs-at-risk (OARs) dose limits and the tumor edge dose limits. The dose distributions of the CyberKnife-based SCART and pSCART plans were compared using five criteria: i) prescription dose; ii) 80% prescription dose volume, targets coverage at 80% and 20% dose levels, and the 80%/20% ratio; iii) volume receiving >5 Gy outside the tumor edge; iv) dose tolerance limits to OARs; and v) mean dose to OARs.ResultspSCART can deliver a higher prescription dose of 24 Gy × 3 fractions versus SCART’s 15 Gy × 2–3 fractions or 18 Gy × 2 fractions. Specifically, pSCART outperforms SCART in terms of the 80% prescription dose volume and 80% dose level coverage of stereotactic centralized/core target volumes (SCTV) achieving 69.77%–100.00% versus SCART’s 43.6%–99.5%. The 20% dose level coverage for gross target volume (GTV) is slightly lower for pSCART, achieving 88.96%–98.64% versus SCART’s 90.1%–99.9%. The maximum point dose outside the target volume is lower for pSCART at 4.58–6.19 Gy versus SCART’s 4.78–6.67 Gy; additionally, the V5Gy at the tumor edge is significantly smaller for pSCART at 5.93–23.72 cm3 versus SCART’s 6.85–151.66 cm3. The average dose to most OARs in the pSCART plan is lower than in the SCART plan.ConclusionsThis work provides initial insights into evaluating treatment plans for bulky tumors using pSCART. Compared to the CyberKnife SCART, pSCART generates significantly higher prescription doses and larger high-dose regions within the GTV while delivering lower doses at the tumor edge, enhancing normal tissue sparing.